Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is in the process of issuing H-shares and listing on the Hong Kong Stock Exchange, with various steps completed in the application and approval process [1][2][3][4]. Group 1: Application and Approval Process - The company submitted its application for H-share issuance to the Hong Kong Stock Exchange on July 10, 2024, and published the application materials on the same day [2]. - The company resubmitted its application on January 21, 2025, and September 29, 2025, in accordance with the Hong Kong Stock Exchange's regulations [2]. - On December 11, 2024, the China Securities Regulatory Commission confirmed the company's application for overseas issuance and listing [3]. - The Hong Kong Stock Exchange's listing committee held a hearing on December 19, 2024, to review the company's application [3]. Group 2: H-share Offering Details - The total number of H-shares to be issued is 8,634,300, with 863,500 shares allocated for public offering in Hong Kong, representing approximately 10% of the total, and 7,770,800 shares for international offering, representing approximately 90% [6]. - The price range for the H-share issuance is preliminarily set between HKD 347.50 and HKD 389.00 [6]. - The public offering in Hong Kong commenced on November 7, 2025, and is expected to conclude on November 12, 2025, with the issuance price to be announced by November 14, 2025 [6]. - The H-shares are anticipated to be listed and commence trading on the Hong Kong Stock Exchange on November 17, 2025 [6].
四川百利天恒药业股份有限公司 关于刊发H股招股说明书、H股发行价格区间及H股香港公开发售等事宜的公告